Clinica Baviera (XMAD:CBAV) Beneish M-Score: -3.11 (As of Jun. 24, 2026)


XMAD:CBAV Clinica Baviera SA XMAD:CBAV
100 GF Score
Price €56.60
GF Value €41.29
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Clinica Baviera Beneish M-Score?

Clinica Baviera XMAD:CBAV +0.71% 100 Beneish M-Score is -3.11 as of Jun. 24, 2026. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 78.97% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Clinica Baviera's Beneish M-Score or its related term are showing as below:

XMAD:CBAV' s Beneish M-Score Range Over the Past 10 Years
Min: -3.34   Med: -2.86   Max: -2.27
Current: -3.11

During the past 13 years, the highest Beneish M-Score of Clinica Baviera was -2.27. The lowest was -3.34. And the median was -2.86.


Clinica Baviera Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Clinica Baviera's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinica Baviera Beneish M-Score Chart

Clinica Baviera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.76 -3.34 -2.95 -2.35 -3.11

Clinica Baviera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.11 0.00

XMAD:CBAV vs TMO, DHR, IDXX: Beneish M-Score Comparison

For the Diagnostics & Research subindustry, Clinica Baviera's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinica Baviera Beneish M-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Clinica Baviera's Beneish M-Score falls into.


XMAD:CBAV
100GF Score
Clinica Baviera SA XMAD:CBAV
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinica Baviera Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Clinica Baviera for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9034+0.528 * 0.9957+0.404 * 0.9257+0.892 * 1.149+0.115 * 1.015
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9487+4.679 * -0.140509-0.327 * 0.995
=-3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €4.7 Mil.
Revenue was €301.8 Mil.
Gross Profit was €267.8 Mil.
Total Current Assets was €59.3 Mil.
Total Assets was €247.5 Mil.
Property, Plant and Equipment(Net PPE) was €142.9 Mil.
Depreciation, Depletion and Amortization(DDA) was €23.9 Mil.
Selling, General, & Admin. Expense(SGA) was €38.7 Mil.
Total Current Liabilities was €61.5 Mil.
Long-Term Debt & Capital Lease Obligation was €57.5 Mil.
Net Income was €42.1 Mil.
Gross Profit was €0.0 Mil.
Cash Flow from Operations was €76.8 Mil.
Total Receivables was €4.6 Mil.
Revenue was €262.6 Mil.
Gross Profit was €232.1 Mil.
Total Current Assets was €47.7 Mil.
Total Assets was €212.4 Mil.
Property, Plant and Equipment(Net PPE) was €122.7 Mil.
Depreciation, Depletion and Amortization(DDA) was €20.9 Mil.
Selling, General, & Admin. Expense(SGA) was €35.5 Mil.
Total Current Liabilities was €50.4 Mil.
Long-Term Debt & Capital Lease Obligation was €52.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.731 / 301.782) / (4.558 / 262.648)
=0.015677 / 0.017354
=0.9034

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(232.084 / 262.648) / (267.807 / 301.782)
=0.883631 / 0.887419
=0.9957

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (59.337 + 142.854) / 247.508) / (1 - (47.723 + 122.662) / 212.394)
=0.183093 / 0.197788
=0.9257

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=301.782 / 262.648
=1.149

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(20.88 / (20.88 + 122.662)) / (23.897 / (23.897 + 142.854))
=0.145463 / 0.143309
=1.015

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(38.657 / 301.782) / (35.463 / 262.648)
=0.128096 / 0.135021
=0.9487

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((57.48 + 61.466) / 247.508) / ((52.139 + 50.441) / 212.394)
=0.480574 / 0.48297
=0.995

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.063 - 0 - 76.84) / 247.508
=-0.140509

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Clinica Baviera has a M-score of -3.11 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.11 mean?
Clinica Baviera (XMAD:CBAV) has a Beneish M-Score of -3.11 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Clinica Baviera and its competitors. According to the industry distribution chart, Clinica Baviera ranks #41 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 21%.
Is Clinica Baviera's Beneish M-Score too high?
Clinica Baviera's current Beneish M-Score is -3.11. Based on the distribution chart, Clinica Baviera ranks #41 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #41 out of 195 companies for Beneish M-Score. This places Clinica Baviera in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Clinica Baviera and its competitors. Clinica Baviera's current Beneish M-Score is -3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.29, compared to a current price of €56.60 — trading 37.1% above its estimated fair value. The current Beneish M-Score is -3.11. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Beneish M-Score is -3.11 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued. The current stock price of €56.60 is trading 37.1% above its estimated GF Value™ of €41.29. GuruFocus considers Clinica Baviera to be Significantly Overvalued.

Key valuation signals for XMAD:CBAV:

  • Beneish M-Score: -3.11
  • GF Value™: €41.29 vs. price of €56.60 (37.1% above fair value)
  • GF Score™: 100/100 with 4 warning signs

No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clinica Baviera Business Description

Other Exchanges 0GWJ:UKD9Z:Germany
Address Paseo de la Castellana 20, Madrid, ESP, 28046
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score

Get the complete analysis for XMAD:CBAV

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.60
Price
€41.29
GF Value